Jennison Associates
PRQR icon

Jennison Associates’s ProQR Therapeutics PRQR Stock Holding History

Jennison Associates’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,814,330
Closed -$14.5M – 688
2021
Q4 		$14.5M Sell
1,814,330
-27,248
-1% -$207K 0.01% 409
2021
Q3 		$15.4M Sell
1,841,578
-758,849
-29% -$4.96M 0.01% 402
2021
Q2 		$17.5M Hold
2,600,427
– – 0.01% 388
2021
Q1 		$17.2M Sell
2,600,427
-16,046
-0.6% -$82K 0.01% 374
2020
Q4 		$11M Sell
2,616,473
-17,667
-0.7% -$74.5K 0.01% 395
2020
Q3 		$12.6M Buy
2,634,140
+8,626
+0.3% +$45.1K 0.01% 355
2020
Q2 		$16M Buy
2,625,514
+13,208
+0.5% +$71.3K 0.01% 319
2020
Q1 		$14.3M Sell
2,612,306
-18,320
-0.7% -$141K 0.02% 298
2019
Q4 		$26.1M Buy
2,630,626
+11,614
+0.4% +$90.5K 0.03% 275
2019
Q3 		$15.1M Sell
2,619,012
-229,916
-8% -$1.84M 0.02% 348
2019
Q2 		$25.9M Sell
2,848,928
-39,665
-1% -$468K 0.03% 303
2019
Q1 		$40.1M Sell
2,888,593
-106,712
-4% -$1.59M 0.04% 262
2018
Q4 		$47.3M Sell
2,995,305
-2,789
-0.1% -$51.2K 0.05% 216
2018
Q3 		$58M Buy
2,998,094
+16,889
+0.6% +$180K 0.05% 236
2018
Q2 		$21.8M Buy
2,981,205
+30,831
+1% +$155K 0.02% 386
2018
Q1 		$9.07M Buy
2,950,374
+314,822
+12% +$1.01M 0.01% 464
2017
Q4 		$8.5M Buy
2,635,552
+178,192
+7% +$640K 0.01% 472
2017
Q3 		$11.9M Sell
2,457,360
-15,248
-0.6% -$79.2K 0.01% 464
2017
Q2 		$12.9M Sell
2,472,608
-112,439
-4% -$559K 0.01% 456
2017
Q1 		$12.9M Hold
2,585,047
– – 0.01% 473
2016
Q4 		$12.7M Sell
2,585,047
-31,920
-1% -$164K 0.01% 461
2016
Q3 		$17.5M Sell
2,616,967
-55,410
-2% -$305K 0.02% 431
2016
Q2 		$12.9M Sell
2,672,377
-2,467
-0.1% -$12.7K 0.01% 448
2016
Q1 		$13.1M Buy
2,674,844
+1,673,070
+167% +$8.51M 0.01% 440
2015
Q4 		$8.7M Buy
1,001,774
+33,019
+3% +$380K 0.01% 486
2015
Q3 		$14.1M Buy
968,755
+2,322
+0.2% +$38.9K 0.01% 480
2015
Q2 		$16.1M Buy
966,433
+2,968
+0.3% +$55.9K 0.01% 481
2015
Q1 		$21.1M Buy
963,465
+393,507
+69% +$8.12M 0.02% 433
2014
Q4 		$12.4M Sell
569,958
-60,412
-10% -$917K 0.01% 474
2014
Q3 		$10.8M Buy
+630,370
New +$10.1M 0.01% 478

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jennison Associates's PRQR Position: Q1 2022 in Review

Jennison Associates sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 1,814,330 shares — an estimated $14.5M sold.

Jennison Associates first reported a position in PRQR in Q3 2014 and held it in 30 quarters. The position peaked at $58M in Q3 2018. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

  • Jennison Associates reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Jennison Associates sold 1,814,330 ProQR Therapeutics shares in Q1 2022, an estimated $14.5M.
  • Jennison Associates first reported a position in ProQR Therapeutics in Q3 2014 and held it in 30 quarters.
  • Jennison Associates's ProQR Therapeutics position peaked at $58M in Q3 2018.
  • 58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.